Amandine Mathias, PhD, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland, discusses a project, currently in its early stages, that centers on identifying specific autoantibodies in patients with CNS disorders. With a cohort of fewer than 200 patients, the research aims to pinpoint promising candidates with a high likelihood of autoantibody presence. Once specific autoantibodies are detected, the next step involves antigen discovery. After identifying a CNS antigen, its expression can be enhanced within a cell line, creating a diagnostic tool that can assess the antibody’s presence in a broader patient group. This process is not just diagnostic; if an antibody targets a surface antigen, it can inform therapeutic strategies and potential immunotherapies. This method offers clinicians a refined approach to patient care. This interview took place at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress 2023 in Milan, Italy.
These works are owned by Magdalen dical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.